
Cohance Lifesciences Ltd is Rated Sell
2026-11-22 10:10:06Cohance Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 19 October 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 22 November 2026, providing investors with the most recent and relevant data to assess the company’s outlook.
Read More
Cohance Lifesciences Ltd is Rated Sell
2026-10-31 10:10:03Cohance Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 19 October 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 31 October 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read More
Cohance Lifesciences Ltd Hits Intraday Low Amid Price Pressure on 30 Oct 2026
2026-10-30 13:22:54Shares of Cohance Lifesciences Ltd declined sharply today, touching an intraday low of Rs 445, reflecting a 7.55% drop as the stock underperformed its sector and the broader market amid persistent selling pressure and subdued market sentiment.
Read MoreCohance Lifesciences Gains 5.30%: 4 Key Technical and Fundamental Factors Driving the Week
2026-10-17 12:01:37Key Events This Week 12 Oct: Stock opens at Rs.444.60, gains 0.91% amid Sensex decline 13 Oct: Downgrade to Strong Sell by MarketsMOJO announced; stock falls 1.66% 14 Oct: Technical momentum shifts to mildly bearish; stock rebounds 2.02% 15 Oct: Mixed technical signals as stock gains 2.91% on heavy volume 16 Oct: Weekly close at Rs.463.95 with 1.07% gain; weekly technical trend turns mildly bullish ...
Read More
Cohance Lifesciences Ltd Technical Momentum Shifts Amid Mixed Market Signals
2026-10-16 08:05:05Cohance Lifesciences Ltd has exhibited a notable shift in its technical momentum, moving from a sideways trend to a mildly bullish stance on the weekly charts. Despite this positive development, the company’s overall technical indicators present a complex picture, with mixed signals across key metrics such as MACD, RSI, Bollinger Bands, and moving averages. This analysis delves into the recent technical parameter changes, contextualising them within the broader market and sector performance.
Read More
Cohance Lifesciences Ltd Technical Momentum Shifts Amid Mixed Market Signals
2026-10-15 08:04:44Cohance Lifesciences Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend, reflecting a complex interplay of bullish and bearish signals across key technical indicators. Despite a modest day gain of 2.02%, the stock remains under pressure with a strong sell rating and a challenging long-term performance compared to the broader market.
Read More
Cohance Lifesciences Ltd Downgraded to Strong Sell Amid Weak Financials and Bearish Technicals
2026-10-14 08:49:06Cohance Lifesciences Ltd has been downgraded from a Sell to a Strong Sell rating as of 13 Oct 2026, reflecting deteriorating fundamentals and a shift towards bearish technical indicators. The company’s weak financial performance, expensive valuation, and negative technical trends have collectively triggered this downgrade, signalling caution for investors in the Pharmaceuticals & Biotechnology sector.
Read More
Cohance Lifesciences Ltd Faces Technical Momentum Shift Amid Bearish Signals
2026-10-14 08:06:31Cohance Lifesciences Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, signalling a transition from sideways movement to a mildly bearish trend. Despite some mildly bullish daily moving averages, the broader technical indicators suggest caution for investors as the stock continues to underperform key benchmarks.
Read More
Cohance Lifesciences Ltd Technical Momentum Shifts Amid Bearish Monthly Indicators
2026-10-09 08:06:45Cohance Lifesciences Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend. This transition is underscored by mixed signals from key technical indicators such as MACD, RSI, and moving averages, reflecting a complex market sentiment as the stock navigates a challenging environment.
Read MoreAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
20-Nov-2026 | Source : BSEInvestor Meet
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011
11-Nov-2026 | Source : BSEThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Jasub Property Holdings LLP & Others
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
11-Nov-2026 | Source : BSETranscript of Con call
Corporate Actions
No Upcoming Board Meetings
Cohance Lifesciences Ltd has declared 500% dividend, ex-date: 09 Sep 22
No Splits history available
Cohance Lifesciences Ltd has announced 1:1 bonus issue, ex-date: 25 Sep 20
No Rights history available